Neil Exter, M.B.A., M.S.

Neil Exter is a partner at Third Rock Ventures, which he joined in 2007. At Third Rock, Neil focuses on the formation, development and strategy of new companies. He has more than 30 years of operating, business development and strategy experience across the spectrum of emerging and established biotechnology and technology companies. Neil has held senior operating roles at Constellation Pharmaceuticals, bluebird bio, Foundation Medicine, Pliant Therapeutics, Goldfinch Bio and Cedilla Therapeutics, among others. Prior to joining Third Rock, Neil was chief business officer of Alantos Pharmaceuticals, where he led the sale of the company to Amgen, and earlier, served as vice president for Millennium Pharmaceuticals, directing in-licensing and M&A.

Neil is a member of the investment committee of Mass General Brigham Ventures. Previously, he was a board member and treasurer of the New England Venture Capital Association and a member of the research board at Children’s Hospital.

Neil holds an MBA with highest distinction from Harvard Business School, an M.S. from Stanford University and a B.S. from Cornell University.